Newsletter · · Ashutosh Agarwal

FDA Moves Against Compounded GLP-1s as Eli Lilly's Strong Q1 Lifts Healthcare Stocks - Healthcare Podcast Weekly Digest - May 2 – 8, 2026

Healthcare podcast and news synthesis for May 2–8, 2026. Eli Lilly's blowout Q1 and Foundayo launch, an FDA move against compounded GLP-1s, UnitedHealth's underwriting-cycle inflection, and the AI inflationary-vs-deflationary debate.

Healthcare Podcast Weekly Digest

May 2 – 8, 2026: FDA Moves Against Compounded GLP-1s as Eli Lilly's Strong Q1 Lifts Healthcare Stocks

1. Opening Summary

Healthcare snapped its multi-quarter underperformance this week as Eli Lilly delivered a blowout Q1 (revenue +56% YoY, EPS $8.55 vs. $6.79 consensus), the FDA moved to shut down compounded GLP-1 channels (a major tailwind for LLY/NVO), and UnitedHealth was added to Goldman's Conviction List with the firm calling MA "near the bottom of its underwriting cycle." Beneath the mega-cap headlines, biotech M&A hit $84B in Q1 (best start since 2019), the Trump administration's 100% pharma tariff is reshaping supply chains, and a fierce debate is forming around whether AI in healthcare is currently inflationary (prior-auth bot wars, upcoding) or destined to become deflationary on a 5-10 year horizon.

2. Key People This Week

Speaker Affiliation Key Quote / Take
Steve Kraus Healthcare VC investor (The Heart of Healthcare, May 4) On AI: "Is it in a year? Probably not. But in five years or 10 years…will this technology be deflationary? I'm pretty confident we will."
Michael Esquivel Investor / commentator (The Heart of Healthcare, May 4) On Epic's AI moat: "Being the 800-pound gorilla is not necessarily the ultimate moat."
Scott Becker Becker's Healthcare (Apr 22 episode) On GLP-1 distribution shift: "At one time, you couldn't get a GLP-1 unless you went through…the health systems… Now you have direct marketing directly from… Hims and Hers, the Ro, the Eli Lillys."
Alan Condon Becker's Healthcare ASC analyst (Apr 22) Tenet/USPI deploying "about $250 million a year into ASC acquisitions, into de novo builds…no sign of slowing down."
David Ricks Chair & CEO, Eli Lilly (Apr 30 release) "2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue guidance by $2 billion."
Tim Noel CEO, UnitedHealthcare (May 5) On cutting prior auth 30%: "Prior authorization is an essential safeguard but should only be used when it truly protects patients and improves care."
Carter Gould Cantor Fitzgerald (May 1) LLY PT to $1,230 from $1,205. Highlights "strong OUS Mounjaro demand…encouraging early Foundayo ramp."
Emily Field Barclays (May 5) LLY PT to $1,400 from $1,350. "Strong tirzepatide momentum takes focus back to the big picture."
Mark Cuban "Cost Plus Wellness" launch (referenced Apr 22) Hospitals "might actually be losing the most money on their biggest commercial payer contracts" once factoring in denials, delays, clawbacks.

Sources: The Heart of Healthcare, May 4, 2026; Becker's Healthcare Podcast, Apr 22, 2026; MFNews UNH/LLY tape Apr 28 – May 6, 2026.

3. Hot Topics

Eli Lilly (LLY): The "Foundayo" Launch

  • Q1 print (Apr 30): Revenue $19.8B vs. $17.8B consensus; non-GAAP EPS $8.55 vs. $6.79 consensus.
  • Guidance raised: FY26 EPS to $35.50–$37.00 (from $33.50–$35.00); revenue to $82–$85B (from $80–$83B).
  • Foundayo: First/only approved GLP-1 pill that can be taken any time of day, no food/water restrictions. Ricks: "Foundayo will meaningfully expand the number of people who can benefit from GLP-1s."
  • Foundayo safety scare (May 4): Single FAERS hepatic-failure case in a 56-year-old male caused stock to drop ~3% pre-market to $936.03. Lilly told Wolfe and RBC: "In line with our standard procedures, Lilly Global Patient Safety thoroughly assessed the individual report…and determined it was not reasonably related to Foundayo." RBC called it "baseline noise, not a mechanistic safety signal."
  • Capex (May 6): Additional $4.5B committed across two Indiana Lebanon sites (API + first dedicated genetic medicine manufacturing facility), bringing total Indiana commitments since 2020 to >$21B.
  • Tirzepatide: Generated ~$36B combined Mounjaro/Zepbound sales in 2025, pulling firmly ahead of Novo Nordisk in market share (web research).
  • Sell-side reaction: Cantor PT $1,230 (from $1,205); Morgan Stanley $1,344 (from $1,327); Barclays $1,400 (from $1,350), all Overweight.

UnitedHealth (UNH): Inflection Setup

  • JPMorgan (Apr 28): PT raised to $420 from $389, Overweight maintained.
  • Goldman Sachs (May 1): Added to US Conviction List; firm believes UNH is "nearing the bottom of its underwriting cycle for Medicare Advantage, which presents 40% of its business." Buy rating, $435 PT.
  • Prior auth move (May 5): UnitedHealthcare cut 30% of remaining prior-authorization requirements, with another 30% reduction by year-end (incl. select outpatient surgeries, echocardiograms, certain outpatient therapies and chiropractic care). UNH currently requires PA on only 2% of medical services; 92% are approved in <24 hours. Best-in-class friction profile vs. peers, but the move also appears defensive against the broader managed-care backlash.

GLP-1 Ecosystem

  • FDA 503B move (Apr 30): FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding "no clinical need for outsourcing facilities to compound these drugs from bulk substances." Effectively shuts down legal mass-compounding once shortages resolve. Material tailwind for LLY and NVO branded volumes.
  • Direct-to-consumer pricing: Per Becker (Apr 22), Lilly DTC ~$450/month vs. compounded semaglutide ~$200/month.
  • Medvi fraud case (cited May 4): A 2-person company achieved a multi-billion valuation selling oral semaglutide at $249/month with auto-renewal, fabricating 800 synthetic doctors and 5,000 Meta ads. Kraus noted oral semaglutide had "no viable absorption pathway", a cautionary tale on telehealth/compounding due diligence.
  • Read-throughs: ResMed (RMD) reported double-digit profit growth, with GLP-1 patients more likely to initiate CPAP, unraveling the "GLP-1 kills sleep apnea TAM" bear case. Hims & Hers (HIMS) and Tango Therapeutics carrying ~28-31% short interest into the regulatory shift.

ASC / Surgery Center Consolidation

  • Tenet (THC): Through USPI, operates 533 ASCs and 26 surgical hospitals, largest U.S. ASC operator; deploying ~$250M/yr in acquisitions and de novo builds.
  • Optum/SCA Health (UNH): #2 with 320 centers, ~200 fewer than Tenet.
  • Ascension/AmSurg: Acquiring AmSurg (~250 ASCs) for ~$4 billion, pending final regulatory hurdles.
  • Surgery Partners (SGRY): "A couple of big private equity firms have looked at potentially acquiring [Surgery Partners] over the last couple of years", flagged by Condon as a potential PE takeout candidate.

Sources: Eli Lilly Q1 release, Apr 30, 2026; FDA 503B announcement, Apr 30, 2026; Becker's Healthcare Podcast, Apr 22, 2026; The Heart of Healthcare, May 4, 2026.

4. Key Debates

Debate 1: Is AI in Healthcare Inflationary or Deflationary?

  • Bear (today): Peterson Health Technology Institute (cited May 4) found AI is increasing prior-auth back-and-forth (an "AI bot war" between providers and payers) and enabling more aggressive coding intensity (upcoding risk). U.S. admin waste already runs $250-500B/yr (~25% of healthcare spend).
  • Bull (5-10 years): Kraus: "Will this technology be deflationary? I'm pretty confident we will." Compares current state to "the first automobile." Argues AI "could save value-based care" by improving DCF economics that fail today due to the 12-18 month payment lag after cost absorption.

Debate 2: Can Direct Contracting Disintermediate Managed Care?

  • Bull (Cuban / Becker): "Cost Plus Wellness", no prior auth, no admin fees, ~30-day provider payment. Cuban claims hospitals may lose money on their biggest commercial payer contracts after denials/clawbacks.
  • Bear (incumbent): UNH's prior-auth simplification (May 5) directly counters the friction narrative; deep network effects, data scale, and regulatory moats remain hard to disintermediate at scale.

Debate 3: Is the Lilly Foundayo Liver Signal Real?

  • Bear: Hepatic failure case in a 56-year-old male reported to FAERS Apr 30, stock down 3% pre-market.
  • Bull (RBC, Wolfe): Single case "represents baseline noise, not a mechanistic safety signal"; injectable GLP-1s have shown class-wide hepatic events driven by confounders in obese/T2D populations. Both firms reiterated Outperform; would "be buyers on weakness."

Debate 4: Digital Health, Investable Sector or "Bad Neighborhood"?

  • Public market skeptic: Hinge Health trades at ~5x forward revenue (BofA) despite "unbelievably well performing… super profitable." A public buy-side investor literally asked Kraus whether digital health is "a good company or just the best looking house in a bad neighborhood."
  • Private market bull: Q1 2026 digital health funding hit $4B across 110 deals, 12 mega-rounds = 60% of total. But many privates raising at 10-20x forward, exit-path math is brutal absent a public market re-rate.

Debate 5: Does Epic Have a Real AI Moat?

  • Bear: Northwell Health/Springer Nature meta-study (cited May 4), Epic out-of-the-box AI tools (deterioration, sepsis, readmission, end-of-life, no-show) all failed to surpass AUROC 0.79, with high false positives. 74% of health systems cite EHR dependency as a top AI-adoption barrier (Cuventus).
  • Bull: Epic's 42% acute-care EHR market share = data/distribution moat that point solutions can't replicate at scale.

Sources: The Heart of Healthcare, May 4, 2026; Becker's Healthcare Podcast, Apr 22, 2026; MFNews LLY tape May 4, 2026.

5. Emerging Themes

  1. "AI Bot War" in Prior Authorization: Both providers and payers are deploying competing AI tools, increasing claim back-and-forth volume rather than reducing it. Inflationary near-term effect contrary to the deflationary thesis.

  2. GLP-1 Direct-to-Consumer Becoming Structurally Necessary: Becker argues that running all GLP-1 prescriptions through PCPs at current volumes would be "crushing the system." DTC channels (Hims, Ro, Lilly Direct) aren't optional, they're load-bearing infrastructure.

  3. The "Generalist Specialist" Model: Bob Kocher and Bob Wachter (Health Affairs Scholar, May 2026) propose AI could collapse narrow organ-specific specialties into disease-domain specialists (one AI-augmented clinician managing the entire cardiometabolic domain). Long-dated but enormously disruptive to specialty workforce economics.

  4. Patent-Cliff M&A Acceleration: Big pharma racing to replace >$300B in revenue facing LOE by 2028. Q1 2026 biotech M&A hit $84B (best start since 2019). Sustained dealmaking pace through year-end likely.

  5. Tariff-Driven Premium Inflation: Insurers (incl. Optimum Choice and UnitedHealthcare) have notified states of an additional 2.4-3.6% hike on 2026 health insurance premiums strictly to account for anticipated pharmaceutical cost increases from the Trump admin's 100% pharma tariff. Direct flow-through to consumer.

  6. Site-of-Care Shift Driving Sustained ASC M&A: Health systems "really accelerating their investment in ASCs, outpatient centers." Tenet/USPI and Optum/SCA are dominant consolidators; Surgery Partners flagged as a possible PE buy-out.

  7. Point-Solution AI Beating Bundled EHR AI: Epic's poor AUROC scores create real opportunity for independent clinical decision-support startups.

Sources: The Heart of Healthcare, May 4, 2026; Becker's Healthcare Podcast, Apr 22, 2026; web research, KFF on tariff-driven premiums; BioCentury M&A.

6. Deals & M&A Tracker

Date Acquirer Target Value Notes
Closed Apr 27 BioMarin Amicus Therapeutics $3.65B Cements BMRN's rare-disease portfolio.
Pending (close imminent) Ascension AmSurg (~250 ASCs) ~$4B Pending final regulatory hurdles.
Announced May 6 Bayer Perfuse Therapeutics up to $2.45B Phase 2 eye-disease prospect; Bayer's return to biopharma M&A.
Recent UCB Candid Therapeutics $2B Reverse-merger hijack; entry into autoimmune T-cell engagers.
Recent GSK SiranBio (metabolic oligonucleotide asset) ~$1B Adds to metabolic pipeline.
Recent Madrigal Arrowhead (MASH-focused biobucks deal) ~$1B MASH pipeline build.
Recent Eli Lilly Centessa (CNTA) n/a Mentioned in Alkermes Needham note (May 6); benefits ALKS comp set.
Watch list PE firms Surgery Partners (SGRY) TBD "Maybe that could be another ASC chain that might be up for sale down the line", Condon.

Q1 2026 stat: Biotech M&A deal value hit $84B, strongest start since 2019.

Sources: Eli Lilly Centessa note, May 6 (RX of Alkermes PT raise); Bayer/Perfuse, May 6; BioCentury: Big week for biotech M&A; Becker's Healthcare Podcast, Apr 22, 2026.

7. Regulatory Watch

  • FDA 503B Bulks List (Apr 30): Proposed excluding semaglutide, tirzepatide, and liraglutide, "FDA did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances." Major positive for LLY/NVO branded volumes; negative for compound-heavy DTC players.
  • FDA Foundayo FAERS Case (Apr 30 reported): Single hepatic-failure case in a 56-year-old male; Lilly stated it is "not reasonably related to Foundayo." Watch for follow-up signals.
  • OBBBA Implementation (in effect May 2026): Expanded Medicaid coverage for GLP-1s rolling out this month under the "One Big Beautiful Bill Act"; Medicare Part D coverage slated for January 2027. Massive reimbursement tailwind for LLY/NVO.
  • CMS "ACCESS" Model: CMS Innovation Center launching outcome-aligned payments for technology-enabled chronic care in 2026. Pressure on health systems to evaluate technology partnerships.
  • Trump Admin Pharma Tariffs: 10% universal baseline + 100% tariff on imported patented pharma and APIs; generic, biosimilar, and orphan drugs exempt. GE HealthCare reports reshoring/transfers offset nearly half of expected impact.
  • Imcivree (Rhythm Pharmaceuticals, RYTM): EU Commission approval (May 1) for acquired hypothalamic obesity, following recent US approval.
  • MAHA / Peptides: Push to legalize 19 peptides previously banned in 2023, Kraus calls out the irony given the same movement's vaccine skepticism "with umpteen amounts of data."

Sources: FDA 503B announcement; The Heart of Healthcare, May 4, 2026; advisory.com on premiums; McDermott+ 2026 healthcare regulatory preview; MFNews LLY tape May 4, 2026.

8. Week Ahead

Catalysts and watchpoints for May 9-15, 2026:

  • Q1 earnings tail: Continued reads from Tenet (THC), Cigna (CI), Merck (MRK), Bristol Myers (BMY), Cardinal Health (CAH), Caterpillar-adjacent device suppliers, particularly margin and tariff exposure commentary.
  • GLP-1 prescription tracking: Weekly script data critical post-FDA 503B move. Watch for Mounjaro/Zepbound and Wegovy share shift; oral Wegovy weekly Rx topped 207k in mid-April per web research.
  • Foundayo follow-up: Any additional FAERS case beyond the single May 4 report would meaningfully change the safety narrative.
  • OBBBA Medicaid GLP-1 rollout: First state-by-state coverage data in the back half of May.
  • Surgery Partners (SGRY): Watch for any PE bid chatter following Condon's commentary.
  • Biotech M&A pace: With $84B already done in Q1 and a "big week" the first week of May (per BioCentury), expect continued deal flow as patent-cliff replacement accelerates.
  • Tariff impact in Q2 guidance: Watch for additional medtech mitigation commentary (GE HealthCare, Becton Dickinson have signaled offsets); pharma input cost flow-through hits insurance premium notices.
  • Macro: Real yields and rate-cut path remain the swing factor for long-duration biotech and high-multiple medtech.

Sources: The Heart of Healthcare, May 4, 2026; Becker's Healthcare Podcast, Apr 22, 2026; MFNews LLY/UNH tape Apr 28 – May 6, 2026; web research, tikr.com Wegovy pill data.

Sources